
CLAIMS

Claim 1. A compound of formula I, a stereoisomer or a mixture of stereoisomers thereof, or a pharmaceutically acceptable salt of any of them,



I


wherein:

R^1 and R^2 are each one a radical independently selected from the group consisting of H and (C1-C3)-alkyl;


X is a biradical selected from the group consisting of a biradical of a linear methylene chain of formula $-[CH_2]_n-$ with n = 0, 1 or 2, and a biradical from a branched saturated (C2-C4)-alkylene chain; and

A is either a C-radical from a non-aromatic polycyclic 6- to 15-membered carbocyclic ring system, or a C-radical from a non-aromatic polycyclic 6- to 15-membered heterocyclic ring system having one or two heteroatoms in the ring, the heteroatoms being independently selected from O, S and N; wherein the C-radicals are unsubstituted or the C-radicals have one or more of their H atoms substituted by one or more substituents that are attached to any of the possible substitution positions, the substituents being independently selected from the group consisting of (C1-C4)-alkyl, O[(C1-C4)-alkyl], OH, F, Cl, Br, and I;

on the proviso that radical A does not have any one of the three accompanying unsubstituted formulas, nor any of the possible substituted formulas derived thereof; and




on the proviso that compound I does not have the accompanying formula Ib.



Ib

Claim 2. The compound according to claim 1, wherein A has a formula which is one of the unsubstituted accompanying formulas, or A has a formula which is a modification of the accompanying formulas in which one or more of the H atoms are substituted by one or more substituents which are attached to any of the possible substitution positions, and which are independently selected from the group consisting of (C1-C4)-alkyl, O[(C1-C4)-alkyl], OH, F, Cl, Br, and I.



Claim 3. The compound according to claim 2, wherein A has one of the unsubstituted indicated formulas, or A has a formula which is a modification of the accompanying formulas in which one or more of the H atoms are substituted by one or more substituents which are attached to any of the possible substitution positions, and which are independently selected from the group consisting of CH_3 , CH_2CH_3 , OH , F , and Cl.

Claim 4. The compound according to any one of claims 1-3, wherein biradical X is selected from the group consisting of: a biradical of a linear methylene chain of formula $-[CH_2]_n-$ with n = 0, 1 or 2; and the biradical $-CH(CH_3)-$.

Claim 5. The compound according to claim 4, wherein biradical X is a biradical of a linear methylene chain of formula $-[CH_2]_n-$ with n = 0, 1 or 2.

Claim 6. The compound according to claim 5, wherein n = 0, biradical X being a single

bond.


Claim 7. The compound according to any one of claims 1-6, wherein R^1 is H or CH_3 .

Claim 8. The compound according to claim 7, wherein R^1 is H.


Claim 9. The compound according to any one of claims 1-8, wherein R^2 is H or CH_3 .

Claim 10. The compound according to claim 9, wherein R^2 is CH_3 .


Claim 11. The compound according to claim 1, having a formula independently selected from the group consisting of accompanying formulas Ia, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, Im, Io, Ip, Iq, Ir, Is, It, Iu, Iv, Iw, Ix, Iy, Iz, Iaa, Iab and Iac.




Ia




Iu




Ic




Id




Ie




If




Ig




Ih




Ii




Ij




Ik




Im




Io




Ip




Iq




Ir




Is




It




Iv




Iw




Ix




Iy




Iz



Iaa



Iab




Iac

Claim 12. A pharmaceutical composition comprising an effective amount of a compound as defined in any one of claims 1-11, together with adequate amounts of pharmaceutically acceptable excipients or carriers.

Claim 13. A compound as defined in any one of claims 1-11, for use as an active pharmaceutical ingredient.

Claim 14. Use of a compound as defined in any one of claims 1-11 or as defined by accompanying formula Ib, in the manufacture of a medicament for the prevention or treatment of Alzheimer's disease in an animal, including a human.



Ib